ライフサイエンスコーパス: efficacy and safety

1 Further controlled studies should evaluate its efficacy and safety.

2 oparticle biodistribution is essential for evaluating their efficacy and safety.

3 l treatments, and on the consistency of evidence, degree of efficacy, and safety.

4 Efficacy and safety analyses were by intention to treat.

5 during the maintenance period were included in the primary efficacy and safety analyses.

6 pproval from regulatory agencies, and for this reason their efficacy and safety are rarely proven.

7 her rigorous clinical studies are needed to determine their efficacy and safety, as well as the appropriate patient candi

8 molar affinity CAR T cells demonstrated superior anti-tumor efficacy and safety compared to their nanomolar counterparts.

9 The study generated informative efficacy and safety data regarding the use of olaparib in com

10 cholesterol concentrations achieved at 4 weeks and clinical efficacy and safety in the FOURIER trial of evolocumab, a mon

11 The efficacy and safety of 0.005% calcipotriol ointment combined

12 To compare the efficacy and safety of 2 sclerosants used to treat reticular

13 Evidence exists for the efficacy and safety of 6-month isoniazid monotherapy, rifampi

14 Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA

15 lind, randomized, placebo-controlled trial, we assessed the efficacy and safety of adalimumab in children and adolescents

16 The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel bl

17 It was the aim of this study to evaluate feasibility, efficacy and safety of ADVOS in the first 14 patients ever tr

18 ompositional differences among extracts that may affect the efficacy and safety of allergen immunotherapy.

19 e authors performed an updated meta-analysis evaluating the efficacy and safety of CAS versus CEA, given recently publish

20 We aimed to assess the efficacy and safety of ceftazidime-avibactam in patients with

21 We assessed the efficacy and safety of ceritinib versus platinum-based chemot

22 We aimed to analyse the efficacy and safety of clemastine fumarate as a treatment for

23 This study confirms the efficacy and safety of CM-OIT as well as the role of iNKT cel

24 We investigated the efficacy and safety of early hen's egg introduction at age 4

25 Data regarding the long-term efficacy and safety of everolimus-eluting bioresorbable vascu

26 The efficacy and safety of fixed-dose combination of AM and PQP w

27 We aimed to test the efficacy and safety of graded exercise delivered as guided se

28 We sought to evaluate the efficacy and safety of grass pollen intradermal immunotherapy

29 We aimed to assess the efficacy and safety of idelalisib in combination with a secon

30 to synthesize, appraise, and present all SR evidence on the efficacy and safety of inhaled short-acting bronchodilators t

31 This preplanned analysis assessed the efficacy and safety of IRd vs placebo-Rd according to cytogen

32 lacebo-controlled, phase 3, crossover trial to evaluate the efficacy and safety of ivacaftor alone or in combination with

33 ic review and meta-analysis of the published reports on the efficacy and safety of IVC filters.

34 omized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of levosimendan in patients with a left v

35 Conclusion The durable clinical efficacy and safety of MR imaging-guided HIFU were demonstrat

36 se II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-

37 dose-escalation, phase I CheckMate 016 study evaluated the efficacy and safety of nivolumab plus ipilimumab in combinati

38 Dietary assessment and modelling are required to monitor efficacy and safety of ongoing strategic vitamin D fortificat

39 We aimed to assess the efficacy and safety of pacritinib versus best available thera

40 This phase 2 study was designed to test the efficacy and safety of pembrolizumab, a humanized PD-1-blocki

41 To evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re

42 To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T

43 We assessed the efficacy and safety of re-treating malaria patients with unco

44 We aimed to assess the efficacy and safety of regorafenib in patients with HCC who h

45 Therefore, we assessed the efficacy and safety of sofosbuvir and ledipasvir in renal tra

46 ts from recent studies strengthen the evidence base for the efficacy and safety of sublingual immunotherapy in patients w

47 We investigated the efficacy and safety of switching to a single-tablet regimen o

48 This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a huma

49 We summarise efficacy and safety results from 13 polypill trials (9059 par

50 The efficacy and safety were assessed for up to 4 months.